Cyclic Peptides Patents (Class 530/317)
-
Patent number: 9334306Abstract: The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (LSCs) and targeted therapy against leukemia mediated at least in part by CLL1-expressing LSCs.Type: GrantFiled: July 9, 2012Date of Patent: May 10, 2016Assignee: The Regents of the University of CaliforniaInventors: Chong-xian Pan, Hongyong Zhang
-
Patent number: 9328139Abstract: Structural and functional analysis of peptide inhibitor binding to the cyclin D1 groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of proliferative diseases including cancer and inflammation.Type: GrantFiled: September 4, 2013Date of Patent: May 3, 2016Assignee: University of South CarolinaInventors: Campbell McInnes, Shu Liu
-
Patent number: 9321779Abstract: The present invention relates to an intermediate, as represented by formula (I), for synthesizing caspofungin, and a preparation method thereof. The intermediate enables efficient preparation of caspofungin.Type: GrantFiled: March 21, 2012Date of Patent: April 26, 2016Assignee: UniTris Biopharma Co., Ltd.Inventors: Fuyao Zhang, Xiaoming Shen, Gaoqiang Hu, Piaoyang Sun
-
Patent number: 9321809Abstract: A compound as represented by Formula (I) is provided, wherein groups are defined in the description. The compound is used as HCV protease inhibitor for treating HCV infection.Type: GrantFiled: December 5, 2012Date of Patent: April 26, 2016Assignee: GINKGO PHARAMA CO., LTD.Inventors: Ben Li, Li Chen, Peibing Zhai, Tao Jiang
-
Patent number: 9309288Abstract: The present invention is related to new peptide antagonists of ?v?3 receptor, designed on the basis of the crystal structure of integrin ?v?3 in complex with c(RGDf[NMe]V) and the NMR structure of echistatin. These peptides are potent and selective antagonists of the ?v?3 receptor and can be used as novel anticancer drugs and/or new class of diagnostic non-invasive tracers as suitable tools for ?v?3-targeted therapy and imaging.Type: GrantFiled: August 30, 2013Date of Patent: April 12, 2016Assignee: ADVANCED ACCELERATOR APPLICATIONSInventors: Annarita Del Gatto, Laura Zaccaro, Carlo Pedone, Michele Saviano
-
Patent number: 9273098Abstract: Lactam-bridged melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes, including obesity, modulation of feeding behavior, related metabolic syndrome, sexual dysfunction, male erectile dysfunction and female sexual dysfunction.Type: GrantFiled: December 6, 2011Date of Patent: March 1, 2016Assignee: Palatin Technologies, Inc.Inventors: Xin Chen, Wei Yang
-
Patent number: 9273099Abstract: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.Type: GrantFiled: October 4, 2011Date of Patent: March 1, 2016Assignees: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Loren D. Walensky, Stanley J. Korsmeyer, Susan Korsmeyer, Gregory Verdine
-
Patent number: 9233318Abstract: A purification method of the compound represented by formula 1 is provided, which includes the following steps: (1) loading crude compound 1 on macroporous adsorbent resin, (2) washing the macroporous adsorbent resin with an aqueous solution, an organic solvent or a mixture solution of organic solvent and water, (3) eluting with an aqueous solution, an organic solvent or a mixture solution of organic solvent and water. The purified compound represented by formula 1 is obtained.Type: GrantFiled: April 15, 2011Date of Patent: January 12, 2016Assignee: SHANGHAI TECHWELL BIOPHARMACEUTICAL CO., LTD.Inventors: Zhonghao Zhuo, Zhijun Tang, Tianhui Xu, Ming Li, Xiaoming Ji, Xiaoliang Gao
-
Patent number: 9155696Abstract: A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceutically active agent and less than 0.5% of an biologically acceptable organic solvent.Type: GrantFiled: August 11, 2009Date of Patent: October 13, 2015Assignee: Novartis AGInventor: Karin Schönhammer
-
Patent number: 9096647Abstract: A non-aqueous single pot synthesis of [18F]SFB is set forth. The [18F]SFB produced with this method is then used, for example, to label a peptide or an engineered antibody fragment (diabody) targeting human epidermal growth factor receptor 2 (HER2) as representative examples of labeled compounds for use as an injectable composition to locate abnormal tissue, specifically tumors within an animal or human using a PET scan.Type: GrantFiled: June 21, 2013Date of Patent: August 4, 2015Assignee: The Regents Of The University Of CaliforniaInventors: Sebastian Olma, Clifton Kwang-Fu Shen
-
Patent number: 9090655Abstract: Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N?2.Type: GrantFiled: March 29, 2011Date of Patent: July 28, 2015Assignee: RISE TECHNOLOGY CO., LTD.Inventors: Jya-Wei Cheng, Kuo-Chun Huang, His-Tsu Cheng, Hui-Yuan Yu
-
Patent number: 9073963Abstract: The invention relates to compositions which are useful for inhibiting prostaglandin F2? receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.Type: GrantFiled: April 15, 2009Date of Patent: July 7, 2015Assignees: Universite De Montreal, Theratechnologies, Inc.Inventors: Krishna Peri, Felix Polyak, William Lubell, Eryk Thouin, Sylvain Chemtob
-
Patent number: 9067968Abstract: The invention provides tight junction protein modulators, compositions comprising the same, and uses thereof. In particular, the invention provides tight junction protein modulators that modulate the second extracellular loop of tight junction proteins, such as occludin or claudin.Type: GrantFiled: October 21, 2013Date of Patent: June 30, 2015Assignee: The Regents of the University of Colorado, a body corporateInventors: Margaret C. Neville, Neal Beeman, Robert S. Hodges
-
Publication number: 20150148290Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: ApplicationFiled: October 31, 2014Publication date: May 28, 2015Inventors: Eric Marsault, Carl St-Louis
-
Patent number: 9040487Abstract: The present invention relates to a cyclosporine emulsion containing: i) a cyclosporine ii) a natural oil (long chain triglyceride) iii) a phosphatidylcholine, iv) glycerol, v) a pharmaceutically tolerable alkali salt of a free fatty acid, vi) a medium chain triglyceride-oil vii) optionally, hydrochloric acid or sodium hydroxide for pH adjustment viii) water.Type: GrantFiled: September 30, 2011Date of Patent: May 26, 2015Assignee: NEUROVIVE PHARMACEUTICAL ABInventor: Eskil Elmér
-
Patent number: 9035021Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: GrantFiled: March 16, 2011Date of Patent: May 19, 2015Assignee: Novartis AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Publication number: 20150133305Abstract: The present invention is directed to methods, for example phage display assays, for bioengineering peptides that bind to individual distinct nucleotides. Also provided are peptides engineered by such methods. Specifically, cyclic peptides that bind individual distinct nucleotides are provided herein.Type: ApplicationFiled: November 7, 2008Publication date: May 14, 2015Inventors: Mineo Yamakawa, Joseph V. Kosmoski, Deane C. Little
-
Publication number: 20150132355Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.Type: ApplicationFiled: November 12, 2014Publication date: May 14, 2015Inventors: William D. Carlson, Peter C. Keck, Michael Sworin, Dattatreyamurty Bosukonda
-
Publication number: 20150132374Abstract: A modified release composition comprising cyclosporin A for oral administration. The composition may comprise a core and a modified release coating, wherein the core comprises a hydrogel-forming polymer matrix and cyclosporin A. The composition may be in the form of a minibead. The compositions provide a pharmacokinetic profile and dissolution profile which provides release of cyclosporin A in the lower GI tract whilst minimising systemic exposure. Also disclosed are uses of the composition in the treatment of conditions affecting the lower GI tract, particularly the colon.Type: ApplicationFiled: November 7, 2014Publication date: May 14, 2015Applicant: SIGMOID PHARMA LIMITEDInventors: Ivan Coulter, Vincenzo Aversa, Mónica Rosa
-
Publication number: 20150132220Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: ApplicationFiled: January 8, 2015Publication date: May 14, 2015Inventors: Philip E. Thorpe, Jin He
-
Publication number: 20150133630Abstract: An object of the present invention is to provide molecules that bind to a target molecule in a pH dependent manner and a screening method for selecting such molecules. Provided is a screening method for selecting peptides that bind to a target molecule at a first pH and do not bind thereto at a second pH, including a step of preparing a peptide library in which each mRNA contains at least one special amino acid that undergoes a pH-dependent change in the charge of the side chain thereof, a step of bringing the peptide library into contact with the target molecule and incubating them under the first pH condition and selecting peptides that bind to the target molecule, and a step of selecting, from the peptides which have bound to the target molecule, peptides that do not bind to the target molecule under the second pH condition.Type: ApplicationFiled: June 6, 2013Publication date: May 14, 2015Applicant: The University of TokyoInventors: Hiroaki Suga, Takeo Iida
-
Patent number: 9029501Abstract: Disclosed embodiments concern a method for making substantial quantities of desired macrocycles. Disclosed ring closing reactions make the macrocycle with desired olefin geometry in excellent yield and E/Z ratio. Particular embodiments of the current method concern intermediates that are obtained from commercially available starting materials in a small number of steps, thereby illustrating the commercial importance and applicability of the disclosed method. The macrocycle produced by the ring closing reaction can be further derivatized to provide analogs of the macrocyclic compounds.Type: GrantFiled: November 1, 2011Date of Patent: May 12, 2015Assignee: Rigel Pharmaceuticals, Inc.Inventors: Thilo J. Heckrodt, Rajinder Singh
-
Publication number: 20150125423Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.Type: ApplicationFiled: January 12, 2015Publication date: May 7, 2015Inventors: Jennifer Mitcham, Matthew Moyle
-
Patent number: 9023808Abstract: Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein the dashed line, X, R1, R2, R3, R4, R5, R6, and R7 have defined meanings; the preparation thereof; compositions containing compounds of formula (I), including bioavailable combinations with ritonavir; and the pharmaceutical uses thereof.Type: GrantFiled: January 16, 2008Date of Patent: May 5, 2015Assignees: Medivir AB, Janssen R&D IrelandInventors: Kenneth Alan Simmen, Herman Agustinus De Kock, Carl Erik Daniel Jonsson, Karl Magnus Milsson, Bengt Bertil Samuelsson, Asa Annica Kristina Rosenquist, Susana Ayesa Alverez, Bjorn Olaf Classon, Hans Kristian Wallberg
-
Publication number: 20150119318Abstract: The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject.Type: ApplicationFiled: July 9, 2014Publication date: April 30, 2015Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Lilia I. Melnik, Robert F. Garry, Cindy A. Morris
-
Patent number: 9018349Abstract: The present invention relates to a novel process for preparing the aza cyclohexapeptide compound 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0 (caspofungin) represented by the following formula 1, which can improve the problem due to a pungent odor and toxicity during the process and can prepare caspofungin as a final product at high yield compared to conventional processes, and to novel intermediates which are used in the preparation process:Type: GrantFiled: January 12, 2011Date of Patent: April 28, 2015Assignee: CKD Bio Corp.Inventors: Heui-Il Kang, Yun-Beom Ham, Su-Hyun Kyong, Heung-Mo Kang, Tae-Hee Han, Doo-Jin Kang
-
Patent number: 9012405Abstract: The present invention concerns a chimeric polypeptide, capable of detecting the antibodies generated in rheumatoid arthritis, comprising at least two citrulinated peptide subunits: (i) one derived from the ? or ? chain of the fibrin and (ii) a second derived from the filaggrin. In addition, the invention comprises an antigenic composition, a method and a kit for the diagnosis of rheumatoid arthritis, from the detection of the autoantibodies generated during the course of said disease.Type: GrantFiled: April 30, 2008Date of Patent: April 21, 2015Assignees: Consejo Superior de Investigaciones Cientificas, Fundacio Clinic per a la Recerca BiomedicaInventors: Isabel Haro Villar, José M. Gomora Elena, Luisa M Perez Rodríguez, Raimon Sanmarti Sala
-
Patent number: 9012603Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.Type: GrantFiled: December 18, 2009Date of Patent: April 21, 2015Assignee: Biogen Idec Hemophilia Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
-
Publication number: 20150105328Abstract: The invention concerns peptoid-peptide hybrids that may act as protein interaction inhibitors (PPIIs). Another aspect of the invention concerns a method for treating a disorder (e.g., an oncologic disorder) in a human or animal subject, comprising administering an effective amount of a peptoid-peptide hybrid (a peptoid body) of the invention, or a composition comprising a peptoid-peptide hybrid, to the subject in need thereof. Another aspect of the subject invention concerns a method for killing or inhibiting the growth of cells (e.g., cancer cells or malaria-infected cells), comprising contacting a cancer cell in vitro or in vivo with an effective amount of a peptoid-peptide hybrid, or a composition comprising the peptoid-peptide hybrid. Another aspect of the invention concerns a method for producing a peptoid-peptide hybrid.Type: ApplicationFiled: December 18, 2014Publication date: April 16, 2015Inventors: MARK MCLAUGHLIN, PRIYESH JAIN
-
Publication number: 20150105331Abstract: A high purity cyclopeptide crystal has a structure shown by Formula I. R represents H or a cation forming a pharmaceutically acceptable salt. Also disclosed are a preparation method and a use of the high-purity cyclopeptide crystal.Type: ApplicationFiled: March 29, 2013Publication date: April 16, 2015Inventors: Shidong Liu, Zhaoli Zhang, Xiusheng Wang, Xiao Zhang, Zhijun Tang, Xiaoming Ji
-
Patent number: 9006173Abstract: This invention relates to the use of microcystins as agents for treatment of cancer. Also provided are methods of screening for microcystins with improved cytotoxicity.Type: GrantFiled: May 10, 2007Date of Patent: April 14, 2015Assignee: University of Kentucky Research FoundationInventors: Noel R. Monks, Shuqian Liu, Jeffrey A. Moscow
-
Patent number: 9006391Abstract: The present invention relates to a method for preparing cyclopeptides by means of protection with a substituted boronic acid. The present invention also discloses novel boronate esters of cyclopeptides of general formula (8).Type: GrantFiled: May 6, 2010Date of Patent: April 14, 2015Assignee: DSM Sinochem Pharmaceuticals Netherlands B.V.Inventors: Robertus Mattheus De Pater, Dhiredj Chandre Jagesar, Thomas Van Der Does
-
Patent number: 9006392Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.Type: GrantFiled: February 1, 2011Date of Patent: April 14, 2015Assignee: Novacta Biosystems LimitedInventors: Michael John Dawson, Antony Nicholas Appleyard, Jesus Cortes Bargallo, Sjoerd Nicolaas Wadman
-
Publication number: 20150098905Abstract: The present invention relates to targeting agents and methods: of using the targeting agents to detect a fungal cell in a subject.Type: ApplicationFiled: May 8, 2013Publication date: April 9, 2015Applicant: Rutgers, The State University of New JerseyInventors: David S. Perlin, Guillermo Garcia-Effron, Arkady Mustaev
-
Publication number: 20150099658Abstract: The present application provides stable peptide-based anti-gp41 antibody capture agents and methods of use as detection and diagnosis agents. The application further provides methods of manufacturing anti-gp41 antibody capture agents using iterative on-bead in situ click chemistry.Type: ApplicationFiled: September 12, 2014Publication date: April 9, 2015Inventors: Jessica A. Pfeilsticker, Aiko Umeda, James R. Heath
-
Patent number: 8987194Abstract: A Nisin derivative or variant, comprising an amino acid substitution at amino acid position 29 in the amino acid sequence. The Nisin derivative exhibits enhanced antimicrobial activity when compared to wild type Nisin. The Nisin derivative has an application as a natural food additive and as a therapeutic agent.Type: GrantFiled: December 22, 2010Date of Patent: March 24, 2015Assignees: University College Cork-National University of Ireland, Cork, Agriculture and Food Development AuthorityInventors: Colin Hill, Paul Cotter, Paul R. Ross, Desmond Field
-
Patent number: 8987414Abstract: Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.Type: GrantFiled: February 14, 2013Date of Patent: March 24, 2015Assignee: Aileron Therapeutics, Inc.Inventors: Vincent Guerlavais, Christopher R. Conlee, Scott Paul Lentini
-
Patent number: 8987413Abstract: The invention relates to a method or process for the chemical manufacture of depsipeptides of the formula I employing an aldehyde acetal intermediate, wherein the symbols have the meaning defined in the description, to new intermediates and their manufacture, as well as related invention embodiments.Type: GrantFiled: October 1, 2013Date of Patent: March 24, 2015Assignee: Novartis AGInventors: Murat Acemoglu, Heribert Hellstern, Bernard Riss, Christian Sprecher
-
Publication number: 20150080312Abstract: This invention relates to an isolated, compound of Formula (1) or derivatives or pharmaceutically acceptable salts thereof. The invention also includes all isomeric and tautomeric forms of the compound of Formula (1) or the derivatives thereof. The present invention further relates to processes for the production of the compound of Formula (1) by fermentation of the fungal strain of Actinomycetes (PM0895172/MTCC 684), pharmaceutical compositions comprising the compound of Formula (1) as the active ingredient; and use of the compounds or composition containing them in the treatment of cancer.Type: ApplicationFiled: May 6, 2013Publication date: March 19, 2015Applicant: PIRAMAL ENTERPRISES LIMITEDInventors: Prabhu Dutt Mishra, Sreekumar Sankaranarayanan Eyyammadichiyl, Saji David George, Shailendra Sonawane, Narayan Subhash Chakor, Abhijit Roychowdhury, Rajiv Sharma
-
Publication number: 20150078999Abstract: Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1 Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.Type: ApplicationFiled: June 20, 2014Publication date: March 19, 2015Inventors: James R. Heath, Rosemary Dyane Rohde, Arundhati Nag, Samir Das, Aiko Umeda
-
Patent number: 8981048Abstract: Disclosed are a caspofungin analog, and a preparation method and applications thereof. The caspofungin analog has a structure as represented in Formula 3.Type: GrantFiled: November 10, 2011Date of Patent: March 17, 2015Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.Inventors: Bingming He, Ming Li, Zhijun Tang, Xiaoming Ji
-
Publication number: 20150072396Abstract: Low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations for modifying biomolecules is provided. Compositions, methods, and kits relating to low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations are also provided.Type: ApplicationFiled: March 1, 2012Publication date: March 12, 2015Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Kyle Gee, Upinder Singh, Scott Grecian, Scott Clarke
-
Patent number: 8975368Abstract: Peptide nanotube polymers and methods of making such are disclosed. The peptide nanotube polymers are comprised of alternating monomers of the first peptide ring and monomers of the second peptide ring covalently bonded to one another via a linker, and can be functionalized. The described peptide nanotube polymers can enjoy the combined properties of healing and toughness, self-reporting, and tunability and actuation.Type: GrantFiled: August 12, 2010Date of Patent: March 10, 2015Assignee: The United States of America, as represented by the Secretary of the NavyInventors: John L. Kulp, III, Manoj K. Kolel-Veetil, Thomas D. Clark
-
Patent number: 8975232Abstract: The present invention provides macrocyclic compounds of Formula (I): pharmaceutically acceptable salts thereof; and pharmaceutical compositions thereof, wherein R1, R2, R3, R4, RE, RF, RG, RH, RI, f, g, h, n, and m are as defined herein. The present invention further provides methods of synthesizing these macrocyclic compounds, and methods of their use and treatment. Certain aspects of the present invention relate to modulation of kinase activity, and in the treatment of kinase-associated diseases or disorders.Type: GrantFiled: July 29, 2011Date of Patent: March 10, 2015Assignee: President and Fellows of Harvard CollegeInventors: David R. Liu, Ralph E. Kleiner
-
Publication number: 20150065417Abstract: Disclosed is a high purity cyclopeptide compound, the chemical structure of which is represented by formula (I). R represents H or a cation capable of forming a pharmaceutically acceptable salt, the purity being greater than or equal to 99.0%. Further disclosed are preparation method and use of the high purity cyclopeptide compound.Type: ApplicationFiled: March 29, 2013Publication date: March 5, 2015Inventors: Shidong Liu, Zhaoli Zhang, Xiusheng Wang, Xiao Zhang, Guangjun Jiao, Bingming He, Zhijun Tang, Xiaoming Ji
-
Patent number: 8969513Abstract: Disclosed are a caspofungin analog and applications thereof. The caspofungin analog is a compound having a structure as indicated in Formula (4), or pharmaceutically acceptable salts thereof. R1 can be chosen from hydroxyl, benzyloxy, phenoxy, substituted phenoxy, or substituted benzyloxy. R2, R3, R4, R5 can be chosen from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, benzyloxyphenyl, substituted benzyloxyphenyl, nitro, fluorine, chlorine, bromine, or iodine. Also disclosed are a preparation method for and applications of the compound.Type: GrantFiled: November 10, 2011Date of Patent: March 3, 2015Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.Inventors: Bingming He, Ming Li, Zhijun Tang, Xiaoming Ji
-
Patent number: 8961981Abstract: Compositions and methods for targeting therapeutic agents to neuromuscular junctions are disclosed. Also disclosed are methods for treating diseases and conditions affecting the neuromuscular junction. Compositions include a neuromuscular junction targeting peptide coupled to a therapeutic agent. Compositions may further include a linker peptide. Methods for targeting therapeutic agents to neuromuscular junctions and treating diseases and conditions affecting the neuromuscular junction include administering a composition including a neuromuscular junction targeting peptide coupled to a therapeutic agent.Type: GrantFiled: June 19, 2012Date of Patent: February 24, 2015Assignee: Saint Louis UniversityInventors: Henry Kaminski, Linda Kusner, Namita Satija
-
Patent number: 8962795Abstract: Factor H-binding peptides that binds to a region of factor H that does not impede the complement-inhibitory activity of factor H are disclosed. When immobilized onto the surface of a biomaterial, these peptides recruit factor H, resulting in a substantial inhibition of biomaterial-induced complement activation in a biological substance exposed to the biomaterial.Type: GrantFiled: December 19, 2011Date of Patent: February 24, 2015Assignee: The Trustees of the University of PennsylvaniaInventor: John D. Lambris
-
Publication number: 20150050713Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.Type: ApplicationFiled: July 25, 2014Publication date: February 19, 2015Inventors: Michael P. Malakhov, Fang Fang
-
Publication number: 20150051151Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.Type: ApplicationFiled: March 14, 2013Publication date: February 19, 2015Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Michal Eisenbach-Schwartz, Matityahu Fridkin, Michal Cardon-Yaakov